En randomiseret, dobbeltblind, placebo-kontrolleret, enkelt-stigende dosis undersøgelse i raske frivillige og en dobbelt-blind, placebo-kontrolleret, multipel-stigende dosis undersøgelse i patienter med Parkinsons sygdom for at evaluere sikkerheden, tolerabiliteten og PK /PD af LY3962681 (PROSPECT-PD)
En randomiseret, dobbeltblind (sponsor-ublindet), placebo-kontrolleret, enkelt-stigende-dosis-undersøgelse i raske frivillige og en dobbelt-blind (sponsor-ublindet), placebo-kontrolleret, multiple-stigende-dosis-undersøgelse i patienter med Parkinsons sygdom Sygdom for at evaluere sikkerheden, tolerabiliteten og PK/PD af LY3962681
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3962681 in healthy volunteers and patients with Parkinson's disease.
The study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) study.
During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid [aCSF]) administered intrathecally (into the spinal fluid). During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered intrathecally (into the spinal fluid), 12 to 24 weeks apart.
- The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 dosing days, 12 to 24 weeks apart.
- The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks after Dose 2.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Prevail Therapeutics
- Telefonnummer: 917-336-9310
- E-mail: Prevail.Patients@lilly.com
Studiesteder
-
-
Hampshire
-
Southampton, Hampshire, Det Forenede Kongerige, SO16 6TH
- Ikke rekrutterer endnu
- Southampton General Hospital, NHS Trust
-
Kontakt:
- Danny Pratt
- Telefonnummer: 0044 2381204989
- E-mail: danny.pratt@uhs.nhs.uk
-
-
Oxfordshire
-
Oxford, Oxfordshire, Det Forenede Kongerige, OX3 9DU
- Ikke rekrutterer endnu
- John Radcliffe Hospital
-
-
-
-
Colorado
-
Englewood, Colorado, Forenede Stater, 80113
- Ikke rekrutterer endnu
- CenExel
-
Kontakt:
- Anahaga Champakanath
- Telefonnummer: (303) 867-5468
- E-mail: a.champakanath@cenexel.com
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Ikke rekrutterer endnu
- Institute for Neurodegenerative Disorders
-
Kontakt:
- Anna Carberry
- Telefonnummer: (475) 318-8250
- E-mail: clinicrecruitment@indd.org
-
-
Florida
-
Naples, Florida, Forenede Stater, 34105
- Rekruttering
- Aqualane Clinical Research
-
Kontakt:
- Christopher Webb
- Telefonnummer: (239) 529-6780
- E-mail: christopher@aqualaneresearch.com
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Ikke rekrutterer endnu
- Northwestern University Feinberg School of Medicine Dept of Neurology
-
Kontakt:
- Camryn Butze
- Telefonnummer: (312) 503-6824
- E-mail: camryn.butze@northwestern.edu
-
-
Michigan
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Rekruttering
- Quest Research Institute - Alcanza
-
Kontakt:
- Denise Morgott
- Telefonnummer: (248) 957-8940
- E-mail: Denise.Morgott@questri.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Ikke rekrutterer endnu
- University of Pennsylvania, Dept of Neurology
-
Kontakt:
- Spriha Thapa
- Telefonnummer: (267) 610-8822
- E-mail: Spriha.Thapa@PennMedicine.upenn.edu
-
-
Texas
-
Austin, Texas, Forenede Stater, 78744-1625
- Afsluttet
- Austin Clinic PPD
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Holland, 6525 GA
- Ikke rekrutterer endnu
- Radboud Universitair Medisch Centrum
-
Kontakt:
- Bas Bloem
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Holland, 9713 GZ
- Ikke rekrutterer endnu
- CTC Netherlands BV
-
Kontakt:
- Khalid Abd-Elaziz
- Telefonnummer: 31503055480
- E-mail: khalid.abdelaziz@ctc-netherlands.com
-
-
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekruttering
- Ehime University Hospital
-
Kontakt:
- Akemi Fujita
- Telefonnummer: 089-960-5913
- E-mail: fujita.akemi.aw@ehime-u.ac.jp
-
-
Oita Prefecture
-
Yufu, Oita Prefecture, Japan, 879-5593
- Ikke rekrutterer endnu
- Oita University Hospital
-
Kontakt:
- Tomoko Matsuda
- Telefonnummer: 097-586-6114
- E-mail: to-matsu@oita-u.ac.jp
-
-
Tokyo
-
Hachiōji, Tokyo, Japan, 192-0071
- Rekruttering
- P-One Clinic, Keikokai Medical Corporation
-
Kontakt:
- Yukari Kaneko
- Telefonnummer: 080-8759-9604
- E-mail: kaneko@keikokai-gr.or.jp
-
-
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
- Ikke rekrutterer endnu
- Universitätsklinikum Düsseldorf
-
Kontakt:
- Abraham Nsah Ndifon
- Telefonnummer: +492118108262
- E-mail: abrahamnsah.ndifon@med.uni-duesseldorf.de
-
Münster, North Rhine-Westphalia, Tyskland, 48149
- Ikke rekrutterer endnu
- Universitätsklinikum Münster
-
Kontakt:
- Isabel Aymanns
- Telefonnummer: +492518344427
- E-mail: isabel.aymanns@ukmuenster.de
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study.
- A Montreal Cognitive Assessment score greater than or equal to 24.
MAD study only
- Stable use of background medications at least 8 weeks prior to IP administration, including but not limited to those used for treatment of Parkinson's disease (including deep brain stimulation), and the investigator must expect that participant can tolerate a minimum of 6 months without dose adjustment.
- Participant has a diagnosis of Parkinson's disease per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
- Modified Hoehn and Yahr Stage 1 to 2.5 in the practically defined OFF state.
- A positive result on CSF alpha-synuclein Seed Amplification Assay. (A prior positive result [within 1 year of screening] accepted with sponsor approval if patient did not participate in another Parkinson's disease clinical trial during this period.) (US and Japan only)
- UPSIT score of 20 percentile or less, corrected for age and sex (EU and UK only).
- An abnormal DaT-SPECT consistent with parkinsonism. (History of an abnormal DaTSPECT with the report confirmed by study investigator will be accepted.)
- For participants not taking Parkinson's disease medications, not expected to initiate treatment within 6 months.
- Have a body weight within 40 kg (88 pounds) to 110 kg (242 pounds), inclusive, and body mass index within the range of 17 to 34 kg/m^2, inclusive.
Exclusion Criteria:
- MAD study only: Significant neurological disease affecting the central nervous system other than Parkinson's disease that may be a cause for the participant's clinical symptoms or may confound study objectives.
- Current concomitant disease or serious or unstable illnesses, including central nervous system (SAD study only), cardiovascular, hepatic, renal, gastroenterology, respiratory, endocrinologic, neurologic (MAD study only: other than Parkinson's disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the participant.
- Participant is generally frail or has any medical disorders that, in the opinion of the investigator, could interfere with study-related procedures (including safe performance of IT injection or LP), such as prohibitive spinal diseases, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, or increased intracranial pressure.
- Have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
- MAD study only: Treatment with continuous intestinal delivery Parkinson's disease medication (for example, Duodopa).
- MAD study only: Significant renal impairment (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m^2).
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: LY3962681 (SAD)
Single ascending dose of LY3962681 administered intrathecally (IT) to healthy volunteers. |
IT injection |
|
Placebo komparator: Placebo (SAD)
Single ascending dose of placebo (aCSF) administered intrathecally (IT) to healthy volunteers. |
IT injection |
|
Eksperimentel: LY3962681 (MAD)
Multiple ascending doses of LY3962681 administered IT to participants with Parkinson's disease. |
IT injection |
|
Placebo komparator: Placebo (MAD)
Multiple ascending doses of placebo (aCSF) administered IT to participants with Parkinson's disease. |
IT injection |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst af alvorlige bivirkninger (SAE)
Tidsramme: Op til 76 uger
|
Op til 76 uger
|
|
Hyppighed af akutte behandlingshændelser (TEAE'er)
Tidsramme: Op til 76 uger
|
Op til 76 uger
|
|
Antal afbrydelser på grund af bivirkninger (AE'er)
Tidsramme: Op til 76 uger
|
Op til 76 uger
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
LY3962681 Maksimal observeret koncentration (Cmax)
Tidsramme: Op til 76 uger
|
Op til 76 uger
|
|
Ændring fra baseline i CSF total alfa-synuclein
Tidsramme: Op til 76 uger
|
Op til 76 uger
|
|
LY3962681 area under the concentration versus time curve (AUC)
Tidsramme: Up to 76 weeks
|
Up to 76 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Travis Lewis, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- J5F-MC-OOAA
- 2024-513411-27-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .